diffuse large B cell lymphoma
Conditions
Interventions
Treatment group:prednisone-premedication R-CHOP protocol
Control group:standard R-CHOP regimen
Sponsors
Jiujiang University Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. all of the patients were aged older than 18 years at admission. 2. The diagnosis of DLBCL was confirmed in our pathology department. 3. No marked contraindications of chemotherapy. 4. All patients consented to participate in the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. the patients had a history of rituximab treatment prior to enrollment in the study. 2. The patients refused to participate in the study. 3. The patients were initially diagnosed as central nervous system DLBCL and human immunodeficiency virus-related DLBCL.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Rituximab-related reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactJiang-hua Ding
Jiujiang University Affiliated Hospital
Outcome results
None listed